Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease.
We reported that the activities of phospholipase A2, phosphocholine cytidylyltransferase and phosphoethanolamine cytidylyltransferase, key phospholipid metabolic enzymes, are low in substantia nigra of normal human brain and that this might reduce the ability of nigral neurons to repair damage to cell membranes. To determine whether adaptive changes in nigral phospholipid metabolism can occur in idiopathic Parkinson's disease we compared activities of 11 catabolic and anabolic enzymes in autopsied brain of 10 patients with Parkinson's disease to those in control subjects. Nigral activity of the catabolic enzyme phospholipase A2 was normal in the Parkinson's disease group, whereas that of the biosynthetic enzymes phosphoethanolamine cytidylyltransferase, phosphocholine cytidylyltransferase, and phosphatidylserine synthase were elevated 193, 48 and 38%, respectively, possibly representing a compensatory response to repair membrane phospholipids. Enzyme activities were normal in all other brain areas with the exception of increased (+26%) activity of calcium-stimulated phospholipase A2 in putamen, a change which could be consequent to either decreased dopaminergic striatal input or to a dopamine nerve terminal degenerative process. Our data indicate that the normally low rate of membrane phospholipid synthesis in the substantia nigra, the primary area of neurodegeneration in Parkinson's disease, is increased during the course of the disorder. We suggest that pharmacotherapies which augment this compensatory response might have utility as a treatment for Parkinson's disease.
Ross
B M
BM
Centre for Addiction and Mental Health, University of Toronto, Ontario, Toronto, Canada. brian_ross@camh.net
Mamalias
N
N
Moszczynska
A
A
Rajput
A H
AH
Kish
S J
SJ
D000368:Aged; D000369:Aged, 80 and over; D002462:Cell Membrane / Q000201:enzymology; D019916:Choline-Phosphate Cytidylyltransferase / Q000378:metabolism*; D003566:Cytidine Diphosphate Choline / Q000378:metabolism; D004789:Enzyme Activation / Q000502:physiology; D004983:Ethanolamines / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D018384:Oxidative Stress / Q000502:physiology; D010300:Parkinson Disease / Q000378:metabolism*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D010743:Phospholipids / Q000096:biosynthesis*; D010767:Phosphorylcholine / Q000378:metabolism; D013378:Substantia Nigra / Q000201:enzymology*
D004983:Ethanolamines; D010743:Phospholipids; D010767:Phosphorylcholine; D003566:Cytidine Diphosphate Choline; C005448:phosphorylethanolamine; D019916:Choline-Phosphate Cytidylyltransferase; D010741:Phospholipases A; D054467:Phospholipases A2